Trials / Completed
CompletedNCT03268226
Functional Respiratory Imaging Study (FRI)
Open Label, Prospective, Exploratory Study to Investigate the Effect of Inhaled CHF5993 pMDI on Central and Peripheral Airway Dimensions in COPD Patients by Functional Respiratory Imaging
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of inhaled extrafine CHF5993 pMDI on airway volumes, and resistance, by Functional Respiratory Imaging (FRI), in COPD patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium | An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg) |
Timeline
- Start date
- 2017-11-20
- Primary completion
- 2019-01-30
- Completion
- 2019-01-30
- First posted
- 2017-08-31
- Last updated
- 2020-03-04
Locations
5 sites across 2 countries: Belgium, Hungary
Source: ClinicalTrials.gov record NCT03268226. Inclusion in this directory is not an endorsement.